Who
Mark Lappe
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Inhibrx Biosciences; Chief Executive Officer, Inhibrx; Director and 10% owner, Repros Therapeutics.
In numbers
- Trades disclosed
- 90
- Buys
- 26
- Sells
- 15
- Bought
- $24.6M
- Sold
- $5.2M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 20 Dec 2007
- Last trade
- 14 Oct 2026
- Last filed
- 14 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Oct 2026filed 14 Oct 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $208K2,470 at $84.07 | filing |
| 14 Oct 2026filed 14 Oct 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $210K2,470 at $85.00 | filing |
| 14 Oct 2026filed 14 Oct 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $8,576100 at $85.76 | filing |
| 14 Oct 2026filed 14 Oct 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $206K2,449 at $84.07 | filing |
| 14 Oct 2026filed 14 Oct 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $208K2,451 at $85.00 | filing |
| 14 Oct 2026filed 14 Oct 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $8,576100 at $85.76 | filing |
| 28 Sep 2026filed 28 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $148K1,500 at $98.88 | filing |
| 28 Sep 2026filed 28 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $305K3,000 at $101.70 | filing |
| 28 Sep 2026filed 28 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $148K1,500 at $98.88 | filing |
| 28 Sep 2026filed 28 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $305K3,000 at $101.70 | filing |
| 25 Sep 2026filed 28 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $329K3,324 at $98.87 | filing |
| 25 Sep 2026filed 28 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $217K2,176 at $99.60 | filing |
| 25 Sep 2026filed 28 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $329K3,324 at $98.87 | filing |
| 25 Sep 2026filed 28 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $217K2,176 at $99.60 | filing |
| 8 Sep 2026filed 8 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $585K5,895 at $99.29 | filing |
| 8 Sep 2026filed 8 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $665K6,605 at $100.64 | filing |
| 8 Sep 2026filed 8 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $118K1,100 at $107.12 | filing |
| 8 Sep 2026filed 8 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $54K500 at $108.24 | filing |
| 8 Sep 2026filed 8 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $136K1,219 at $111.88 | filing |
| 8 Sep 2026filed 8 Sep 2026 | INBX Inhibrx BiosciencesBiotechnology | SEC FORM 4 Bought | $1.1M9,681 at $112.28 | filing |
News
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?fool.com · 16 Sep 2026Mark Lappe Purchases 25,000 Shares of Inhibrx Biosciences (NASDAQ:INBX) Stockdailypolitical.com · 8 Sep 2026Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Ligand Pharmaceuticals (NASDAQ:LGND)INBX · tickerreport.com · 23 Oct 2026Insider Buying: Inhibrx Biosciences (NASDAQ:INBX) CEO Acquires $848,982.40 in StockINBX · themarketsdaily.com · 17 Oct 2026Inhibrx Biosciences (NASDAQ:INBX) CEO Purchases $848,982.40 in StockINBX · dailypolitical.com · 15 Oct 2026
2 headlines in the last 90 days name Mark Lappe; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.